Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 2/20 | 0.51 |
| ▸ | NPY2R | P49146 | 2/20 | 0.51 |
| ▸ | NPY4R | P50391 | 2/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332423 | 0.97 | PTH1R (0.55) | PTH1RTFPI | |
| SCHEMBL31332249 | 0.97 | PTH1R (0.55) | PTH1RTFPI | |
| SCHEMBL29862843 | 0.95 | PTH1R (0.57) | PTH1R | |
| SCHEMBL31332426 | 0.95 | PTH1R (0.54) | PTH1RTFPI | |
| SCHEMBL31332065 | 0.93 | PTH1R (0.60) | KEAP1PTH1R | |
| SCHEMBL29863200 | 0.92 | PTH1R (0.61) | KEAP1PTH1RTFPI | |
| SCHEMBL29494169 | 0.91 | KISS1R (0.60) | OPRM1OPRD1OPRK1KISS1RPTH1R | |
| SCHEMBL31332037 | 0.91 | TFPI (0.55) | KEAP1PTH1RTFPI | |
| SCHEMBL30906439 | 0.90 | VIPR1 (0.58) | KEAP1PTH1RTFPI | |
| SCHEMBL30906502 | 0.90 | VIPR1 (0.58) | KEAP1PTH1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12065512-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| EP-4014987-A2 | CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE | Igisu Co., Ltd. (JP) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | OPRM1 4436/4885OPRD1 4112/4885OPRK1 4277/4885 |
| US-12065512-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | OPRM1 4436/4885OPRD1 4112/4885OPRK1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.